性感染症診断薬市場：疾患タイプ、診断方法、デバイスタイプ、エンドユーザー別-2025-2030年世界予測

性感染症診断薬市場は、2023年に1,065億3,000万米ドルと評価され、2024年には1,125億6,000万米ドルに達すると予測され、CAGR 5.97％で成長し、2030年には1,599億7,000万米ドルに達すると予測されています。

性感染症（STD）診断市場の範囲には、HIV、梅毒、淋病、クラミジアなど、性的接触を通じて感染する感染症を特定するために使用される様々な検査や技術が含まれます。診断薬は公衆衛生上不可欠であり、感染の拡大を防ぐための早期発見と治療を可能にします。これらの診断薬の用途は、ヘルスケア施設から家庭用検査キットまで幅広く、病院、クリニック、個人消費者向けのソリューションを提供しています。最終用途分野には、公衆衛生研究所、民間診療所、調査機関などが含まれます。市場の成長は、性の健康に対する意識の高まり、STDの認識と管理に対する政府のイニシアチブの増加、および迅速ポイントオブケア検査や核酸増幅検査などの検査方法の技術的進歩に大きく影響されています。これらの進歩は、より迅速で正確な結果を提供するため、ユーザーの利便性を高め、市場の需要を後押ししています。潜在的なビジネスチャンスは、啓発プログラムが改善され、診断薬の採用が増加している新興市場にあります。診断薬企業とヘルスケアプロバイダーとの戦略的パートナーシップは、リーチとインパクトを強化することができます。しかし、性病にまつわる社会的烙印、高度な診断検査にかかる高額な費用、公衆衛生への介入を制限する規制上のハードルといった課題に直面しています。また、地域間のヘルスケア・インフラの格差がアクセシビリティに影響を及ぼすといった限界もあります。技術革新に最適な分野としては、費用対効果が高く使いやすい在宅検査ソリューションの開発、治療計画を個別化するための人工知能の統合、検査の感度と特異度の向上などが挙げられます。複数の感染症を同時に特定できるマルチプレックス診断の調査は有望です。STD診断市場は、技術革新に牽引されながらも社会的障壁に阻まれるダイナミックな市場であり、企業はヘルスケア提供における文化的コンピテンスに焦点を当て、これらの課題を効果的に乗り越えるために協力関係を構築することを示唆しています。

市場力学：急速に進化する性感染症診断薬市場の主要市場インサイトを公開

性感染症診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の性病有病率の上昇と効果的な診断ソリューションの必要性
  • 性病にまつわるスティグマを軽減するための世界のスクリーニング実施の増加
• 市場抑制要因
  • STDに対する十分な認識と教育の欠如
• 市場機会
  • STDに対する認識と予防のための資金援助と公衆衛生キャンペーンの増加
  • 次世代シーケンサーおよびCRISPRベースの診断における技術革新
• 市場の課題
  • 医薬品承認に関する政府の厳しい規制と未治療の感染症から生じる合併症

ポーターのファイブフォース：性感染症診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：性感染症診断薬市場における外部からの影響の把握

外部マクロ環境要因は、性感染症診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析性感染症診断薬市場における競合情勢の把握

性感染症診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス性感染症診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、性感染症診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨性感染症診断薬市場における成功への道筋を描く

性感染症診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で性病の蔓延が拡大しており、効果的な診断ソリューションの必要性が高まっている
    • 性感染症に関連する偏見を減らすために、世界中で検査の実施を増やす
  • 抑制要因
    • 性感染症に関する十分な認識と教育の欠如
  • 機会
    • 性感染症の啓発と予防のための資金と公衆衛生キャンペーンの増強
    • 次世代シーケンシングとCRISPRベースの診断におけるイノベーション
  • 課題
    • 薬剤承認に対する政府の厳しい規制と未治療の感染症による合併症
• 市場セグメンテーション分析
  • 疾患の種類：次世代シーケンシングとCRISPRベースの診断の進歩により、さまざまなSTDに対応
  • エンドユーザー：複雑なSTD症例に対応するために、臨床および病院の現場でSTD診断の採用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 性感染症診断薬市場：疾患タイプ別

• 細菌性膣炎
• カンジダ膣炎
• クラミジア・トラコマティス/淋菌
• 性器イボ
• B型肝炎
• HIV/エイズ
• マイコプラズマ・ジェニタリウム
• 梅毒
• トリコモナス症

第7章 性感染症診断薬市場診断方法別

• 抗原検出
• 分子診断
• 血清学的検査

第8章 性感染症診断薬市場デバイスタイプ別

• 実験装置
  • 吸光度マイクロプレートリーダー
  • 微分光散乱装置
  • フローサイトメーター
  • ラテラルフローリーダー
  • サーマルサイクラー-PCR
• ポイントオブケアデバイス
  • 電話チップ（マイクロ流体+ICT）
  • 迅速診断キット

第9章 性感染症診断薬市場：エンドユーザー別

• クリニック
• 診断検査室
• 病院
• 公衆衛生機関
• 調査機関

第10章 南北アメリカの性感染症診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の性感染症診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの性感染症診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 英国のスタートアップ企業が性感染症検査機能付きタンポンを発売
  • BioPerfectusが性感染症診断ソリューション用の新しいPCRキットを発売
  • マイラボ、性感染症の迅速検査を開始
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Astra Biotech Gmbh
• Becton Dickinson and company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Danaher Corporation
• Daye Limited
• Diasorin S.p.A
• F. Hoffmann-La Roche Ltd
• Geneproof
• Hologic Inc.
• Jiangsu BioPerfectus Technologies Co., Ltd
• Liferiver Bio-Tech Corp.
• MedMira Inc
• Meridian Bioscience Inc.
• Mylab Discovery Solutions Pvt. Ltd.
• OraSure Technologies, Inc.
• Qiagen Inc
• Quest Consumer Inc.
• Sansure Biotech Inc.
• Seegene Inc.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 58. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 90. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 92. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 94. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 95. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 96. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 98. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 100. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 101. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 112. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 118. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 119. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 124. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 125. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 130. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 131. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 142. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 143. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 148. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 149. THAILAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 154. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 155. VIETNAM SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 166. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 167. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 168. DENMARK SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 173. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 174. EGYPT SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 179. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 180. FINLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 184. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 185. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 186. FRANCE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 191. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 192. GERMANY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 196. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 197. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 198. ISRAEL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 199. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 201. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 203. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 204. ITALY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 209. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 210. NETHERLANDS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 214. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 215. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 216. NIGERIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 220. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 221. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 222. NORWAY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 223. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 225. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 226. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 227. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 228. POLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 229. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 230. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 231. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 233. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 234. QATAR SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 238. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 239. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 240. RUSSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 246. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 257. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 258. SPAIN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 262. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 263. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 264. SWEDEN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 268. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 269. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 270. SWITZERLAND SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 274. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2030 (USD MILLION)
• TABLE 275. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2030 (USD MILLION)
• TABLE 276. TURKEY SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)

T

The Sexually Transmitted Disease Diagnostics Market was valued at USD 106.53 billion in 2023, expected to reach USD 112.56 billion in 2024, and is projected to grow at a CAGR of 5.97%, to USD 159.97 billion by 2030.

The scope of the Sexually Transmitted Disease (STD) Diagnostics market encompasses the various tests and technologies used to identify infections transmitted through sexual contact, including HIV, syphilis, gonorrhea, chlamydia, and more. Diagnostics are essential for public health, enabling early detection and treatment to prevent the spread of infections. Applications of these diagnostics range from healthcare facilities to home-based testing kits, offering solutions for hospitals, clinics, and individual consumers. End-use segments include public health laboratories, private clinics, and research institutes. Market growth is significantly influenced by rising awareness of sexual health, increased government initiatives for STD awareness and control, and technological advancements in testing methods, such as rapid point-of-care tests and nucleic acid amplification tests. These advancements offer faster and more accurate results, thereby enhancing user convenience and boosting market demand. Potential opportunities lie in emerging markets where awareness programs are improving and the adoption of diagnostics is increasing. Strategic partnerships between diagnostic companies and healthcare providers can enhance reach and impact. However, market growth faces challenges such as social stigma associated with STDs, the high cost of advanced diagnostic tests, and regulatory hurdles that can limit public health intervention efforts. Limitations also include disparity in healthcare infrastructure across regions, affecting accessibility. The best areas for innovation include developing cost-effective and user-friendly home testing solutions, integrating artificial intelligence to personalize treatment plans, and improving sensitivity and specificity of tests. Research into multiplex diagnostics that can identify multiple infections simultaneously is promising. The STD Diagnostics market is dynamic, driven by technological innovation yet hindered by societal barriers, suggesting businesses focus on cultural competence in healthcare delivery and form collaborative relationships to navigate these challenges effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sexually Transmitted Disease Diagnostics Market

The Sexually Transmitted Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
  • Increasing implementation of worldwide screening to reduce the stigma associated with STD
• Market Restraints
  • Lack of adequate awareness and education about STDs
• Market Opportunities
  • Increased funding and public health campaigns for STD awareness and prevention
  • Innovations in next-generation sequencing and CRISPR-based diagnostics
• Market Challenges
  • Stringent government regulations for drug approvals and complications arising from untreated infections

Porter's Five Forces: A Strategic Tool for Navigating the Sexually Transmitted Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sexually Transmitted Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sexually Transmitted Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sexually Transmitted Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sexually Transmitted Disease Diagnostics Market

A detailed market share analysis in the Sexually Transmitted Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sexually Transmitted Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sexually Transmitted Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sexually Transmitted Disease Diagnostics Market

A strategic analysis of the Sexually Transmitted Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sexually Transmitted Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech Gmbh, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd, Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., OraSure Technologies, Inc., Qiagen Inc, Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Bacterial Vaginosis, Candidal Vaginitis, Chlamydia Trachomatis/ Neisseria Gonorrhoeae, Genital Warts, Hepatitis B, HIV/AIDS, Mycoplasma Genitalium, Syphilis, and Trichomoniasis.
• Based on Diagnostic methods, market is studied across Antigen Detection, Molecular Diagnostics, and Serologic Testing.
• Based on Device Type, market is studied across Laboratory Devices and Point of Care Devices. The Laboratory Devices is further studied across Absorbance Microplate Reader, Differential Light Scattering Machines, Flow Cytometers, Lateral Flow Readers, and Thermal Cyclers - PCR. The Point of Care Devices is further studied across Phone Chips (Microfluidics + ICT) and Rapid Diagnostic Kits.
• Based on End-Users, market is studied across Clinics, Diagnostic Laboratories, Hospitals, Public Health Agencies, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
    • 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of adequate awareness and education about STDs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
    • 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
  • 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Sexually Transmitted Disease Diagnostics Market, by Disease Type

• 6.1. Introduction
• 6.2. Bacterial Vaginosis
• 6.3. Candidal Vaginitis
• 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
• 6.5. Genital Warts
• 6.6. Hepatitis B
• 6.7. HIV/AIDS
• 6.8. Mycoplasma Genitalium
• 6.9. Syphilis
• 6.10. Trichomoniasis

7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods

• 7.1. Introduction
• 7.2. Antigen Detection
• 7.3. Molecular Diagnostics
• 7.4. Serologic Testing

8. Sexually Transmitted Disease Diagnostics Market, by Device Type

• 8.1. Introduction
• 8.2. Laboratory Devices
  • 8.2.1. Absorbance Microplate Reader
  • 8.2.2. Differential Light Scattering Machines
  • 8.2.3. Flow Cytometers
  • 8.2.4. Lateral Flow Readers
  • 8.2.5. Thermal Cyclers - PCR
• 8.3. Point of Care Devices
  • 8.3.1. Phone Chips (Microfluidics + ICT)
  • 8.3.2. Rapid Diagnostic Kits

9. Sexually Transmitted Disease Diagnostics Market, by End-Users

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals
• 9.5. Public Health Agencies
• 9.6. Research Institutions

10. Americas Sexually Transmitted Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. British startup launches tampon that offers STI screening
  • 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
  • 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astra Biotech Gmbh
• 3. Becton Dickinson and company
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. Danaher Corporation
• 7. Daye Limited
• 8. Diasorin S.p.A
• 9. F. Hoffmann-La Roche Ltd
• 10. Geneproof
• 11. Hologic Inc.
• 12. Jiangsu BioPerfectus Technologies Co., Ltd
• 13. Liferiver Bio-Tech Corp.
• 14. MedMira Inc
• 15. Meridian Bioscience Inc.
• 16. Mylab Discovery Solutions Pvt. Ltd.
• 17. OraSure Technologies, Inc.
• 18. Qiagen Inc
• 19. Quest Consumer Inc.
• 20. Sansure Biotech Inc.
• 21. Seegene Inc.
• 22. Siemens Healthcare GmbH
• 23. Thermo Fisher Scientific, Inc.